Bio Details

Adrienne L. Graves, Ph.D. has served as a director of the company since January of 2024. She previously served as President and Chief Executive Officer of Santen Inc., the United States subsidiary of a publicly traded Japanese pharmaceutical company, from 2002 to 2010 and as Senior Vice President of Worldwide Clinical Development (U.S., Europe, and Japan) from 1995 to 2002. Dr. Graves has served as a member of the boards of directors of Ocular Therapeutix, Inc., a biopharmaceutical company, since July 2023; Nicox S.A., a French ophthalmology company, since 2014, and Surface Ophthalmics, Inc., since 2018, a development stage ophthalmology pharmaceutical company. Previously, Dr. Graves served as a member of the board of directors of IVERIC bio, Inc., a biopharmaceutical company, from late 2018 to 2021 and as the chairman of IVERIC’s board from 2021 to 2023; Greenbrook TMS Inc., a Canadian neurology and medical device company, since 2018 to 2023; Oxurion NV, a Belgian biopharmaceutical company, from 2018 until 2023; Akorn Inc., a pharmaceutical company, from 2012 until late 2018; and TearLab Corporation (now Trukera Medical), a biopharmaceutical company, from 2005 until early 2018. Dr. Graves received a B.A. in psychology from Brown University and a Ph.D. in psychobiology from the University of Michigan and completed a postdoctoral fellowship in visual neuroscience at the University of Paris. Dr. Graves brings to the Board remarkable leadership skills, pharmaceutical development, and operational expertise across the pharmaceutical industry, including having brought multiple ophthalmic products through development to approval and commercialization as well as being responsible for numerous successful acquisitions and partnerships.